jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Advanced Diabetic Package

Diabetes

68 parameters

image

Report in 24Hrs

image

At Home

fastingrequire

Fasting Required

Details

Advanced diabetic package covering insulin, sugar, glucose, iron, liver, kidney, lipid, thyroid, pancreas, blood and electrolytes

₹2,199₹3,900

44% OFF

Parameters

  • List of Tests
    • Microalbumin
    • C-Peptide Fasting
    • Iron Studies
      • Iron
      • TIBC
      • Transferrin Saturation
    • Liver Function Test
      • Albumin
      • Alkaline Phosphatase
      • Bilirubin - Direct
      • Bilirubin - Indirect
      • Bilirubin - Total
      • AST/SGOT
      • ALT/SGPT
      • Total Protein
      • A/G Ratio
      • Gamma GT
      • Globulin
    • Kidney Profile
      • BUN
      • Calcium
      • Creatinine
      • Uric Acid
      • eGFR
      • BUN/Creatinine
      • Urea
    • Lipid Profile
      • Cholestrol/HDL
      • LDL/HDL
      • Non HDL
      • VLDL
      • Total Cholestrol
      • Triglycerides
      • HDL
      • LDL
    • Thyroid Profile
      • Total T3
      • Total T4
      • TSH
    • Hba1c
    • eAG
    • Insulin Fasting
    • Pancreatic Profile
      • Amylase
      • Lipase
    • CBC - Complete Hemogram
    • Serum Electrolytes
      • Na
      • K
      • Cl

Advanced Diabetic Package

  • Why is it done?
    • Comprehensive diabetes screening and monitoring to evaluate glycemic control, pancreatic function, and metabolic status in both newly diagnosed and established diabetic patients
    • HbA1c and eAG assess long-term glycemic control over 2-3 months, helping determine if blood sugar targets are being met
    • Fasting insulin and C-peptide measure pancreatic beta cell function and insulin secretion capacity to determine insulin resistance and diabetes type
    • Kidney profile and microalbumin detect diabetic nephropathy, one of the major microvascular complications of diabetes
    • Liver function tests monitor hepatic metabolism and detect diabetes-related fatty liver disease (NAFLD)
    • Lipid profile assesses cardiovascular risk factors; dyslipidemia is common in diabetics and increases heart disease risk
    • Thyroid profile screens for thyroid disorders, which commonly coexist with diabetes and affect glycemic control
    • Pancreatic profile (amylase and lipase) evaluates pancreatic health and screens for acute or chronic pancreatitis
    • Complete blood count identifies anemia, infection, or hematologic abnormalities common in diabetic patients
    • Iron studies assess iron metabolism and detect hemochromatosis, which can cause secondary diabetes
    • Serum electrolytes monitor sodium, potassium, and chloride levels, which are critical in diabetic patients, especially those with kidney disease or taking certain medications
    • Recommended for initial diabetes diagnosis confirmation, routine diabetes management, pre-treatment evaluation, and annual comprehensive health assessment in diabetic patients
  • Normal Range
    • Microalbumin (Urine): <30 mg/24 hours (normal); 30-300 mg/24 hours (microalbuminuria); >300 mg/24 hours (macroalbuminuria)
    • C-Peptide Fasting: 0.8-3.1 ng/mL (0.26-1.03 nmol/L); indicates residual beta cell function; levels low in Type 1 diabetes, normal or high in Type 2 diabetes
    • Insulin Fasting: 2-12 mIU/mL (14-84 pmol/L) in fasting state; elevated levels suggest insulin resistance
    • Iron: 60-170 mcg/dL (10.74-30.43 mmol/L); Total Iron Binding Capacity (TIBC): 250-425 mcg/dL (44.75-75.98 mmol/L); Transferrin Saturation: 20-50%
    • Albumin: 3.5-5.5 g/dL (35-55 g/L); indicates hepatic protein synthesis and nutritional status
    • Alkaline Phosphatase (ALP): 30-120 IU/L (varies with age and gender); higher in bone disease and cholestasis
    • Bilirubin Total: 0.3-1.2 mg/dL (5.1-20.5 mmol/L); Direct: <0.3 mg/dL (<5.1 mmol/L); Indirect: 0.1-1.2 mg/dL (1.7-20.5 mmol/L)
    • AST/SGOT: 10-40 IU/L; ALT/SGPT: 7-56 IU/L; elevated levels indicate liver cell damage
    • Total Protein: 6.0-8.3 g/dL (60-83 g/L); Globulin: 2.0-3.5 g/dL (20-35 g/L); A/G Ratio: 1.0-2.5
    • Gamma GT (GGT): 0-65 IU/L (varies with age); elevated in liver disease and cholestasis
    • BUN (Blood Urea Nitrogen): 7-20 mg/dL (2.5-7.1 mmol/L); reflects kidney function and protein metabolism
    • Creatinine: 0.7-1.3 mg/dL (62-115 mmol/L); key indicator of glomerular filtration rate and kidney function
    • eGFR (Estimated Glomerular Filtration Rate): >60 mL/min/1.73m² (normal kidney function); <60 indicates chronic kidney disease
    • BUN/Creatinine Ratio: 10-20 (normal); >20 suggests dehydration or prerenal azotemia; <10 suggests overhydration or liver disease
    • Urea: 2.5-7.1 mmol/L (7-20 mg/dL); reflects nitrogen waste from protein metabolism
    • Calcium: 8.5-10.2 mg/dL (2.12-2.55 mmol/L); important for bone health and metabolic function
    • Uric Acid: 3.5-7.2 mg/dL (0.21-0.43 mmol/L) in males; 2.6-6.0 mg/dL (0.15-0.36 mmol/L) in females; elevated in gout and kidney disease
    • Total Cholesterol: <200 mg/dL (<5.18 mmol/L) - desirable; 200-239 mg/dL - borderline; ≥240 mg/dL - high risk
    • LDL Cholesterol: <100 mg/dL (<2.59 mmol/L) - optimal; 100-129 mg/dL - near optimal; ≥160 mg/dL - high; >190 mg/dL - very high
    • HDL Cholesterol: >40 mg/dL (>1.04 mmol/L) in males; >50 mg/dL (>1.30 mmol/L) in females - protective; <40 or <50 - low/risk factor
    • Triglycerides: <150 mg/dL (<1.7 mmol/L) - normal; 150-199 mg/dL - borderline; 200-499 mg/dL - high; ≥500 mg/dL - very high
    • VLDL: 5-40 mg/dL (0.13-1.04 mmol/L) calculated as triglycerides/5
    • Total Cholesterol/HDL Ratio: <5.0 (optimal); cholesterol/HDL and LDL/HDL ratios used to assess cardiovascular risk
    • Non-HDL Cholesterol: Total Cholesterol - HDL; <130 mg/dL is optimal for cardiovascular health
    • Total T3: 80-200 ng/dL (1.2-3.1 nmol/L); Total T4: 4.5-12 mcg/dL (58-154 nmol/L); TSH: 0.4-4.0 mIU/L
    • HbA1c: <5.7% (normal); 5.7-6.4% (prediabetes); ≥6.5% (diabetes); <7% (good diabetes control target); <8% (acceptable)
    • eAG (Estimated Average Glucose): Calculated from HbA1c; <130 mg/dL suggested target for most diabetic patients
    • Amylase: 30-110 IU/L; elevated in pancreatitis or salivary gland disease
    • Lipase: 0-60 IU/L; more specific for pancreatic inflammation than amylase; elevated in pancreatitis
    • Hemoglobin: 13.5-17.5 g/dL in males; 12.0-15.5 g/dL in females; <12.0 in females indicates anemia
    • Hematocrit: 41-53% in males; 36-46% in females; reflects percentage of red blood cells in total blood volume
    • RBC Count: 4.5-5.9 million/mcL in males; 4.1-5.1 million/mcL in females; indicates oxygen-carrying capacity
    • WBC Count: 4.5-11.0 thousand/mcL; elevated in infection or inflammation; decreased in bone marrow disorders
    • Platelets: 150-400 thousand/mcL; important for blood clotting
    • Sodium (Na): 136-145 mEq/L (136-145 mmol/L); critical for fluid balance and nerve function
    • Potassium (K): 3.5-5.0 mEq/L (3.5-5.0 mmol/L); essential for cardiac and skeletal muscle function
    • Chloride (Cl): 98-107 mEq/L (98-107 mmol/L); maintains acid-base balance and osmotic pressure
  • Interpretation
    • Microalbumin: <30 mg/24h indicates normal kidney function; 30-300 mg/24h suggests early diabetic nephropathy requiring intervention; >300 mg/24h indicates advanced kidney disease; useful for detecting kidney disease before serum creatinine becomes elevated
    • C-Peptide Fasting: Low levels (<0.8 ng/mL) indicate little/no insulin production, suggesting Type 1 diabetes or advanced Type 2 diabetes; elevated levels (>3.1 ng/mL) suggest strong insulin production indicating intact beta cell function; ratios compared with glucose help calculate HOMA-IR for insulin resistance assessment
    • Insulin Fasting: Levels >12 mIU/mL suggest insulin resistance, metabolic syndrome, or early Type 2 diabetes; low levels with high glucose indicate inadequate insulin secretion; HOMA-IR (Homeostasis Model Assessment) calculated as (fasting insulin × fasting glucose)/405 with >2.0 indicating insulin resistance; not routinely diagnostic but useful for phenotyping
    • Iron: Elevated iron with high transferrin saturation (>50%) suggests hemochromatosis, which can cause secondary diabetes (hemochromatotic diabetes); low iron indicates iron deficiency anemia; high TIBC with low iron suggests iron deficiency; normal TIBC with high iron suggests hemochromatosis
    • Albumin: Low albumin (<3.5 g/dL) indicates malnutrition, liver disease, or nephrotic syndrome; in diabetics may reflect malnutrition, liver dysfunction, or protein losses in urine; normal albumin helps maintain colloid osmotic pressure
    • ALP Elevation: >120 IU/L may indicate cholestasis, bone disease, hepatic infiltration, or liver dysfunction; in diabetics may suggest metabolic bone disease or fatty liver disease; disproportionate elevation compared to AST/ALT suggests cholestatic pattern
    • Bilirubin Elevation: Total >1.2 mg/dL suggests hemolysis, cholestasis, or hepatic dysfunction; elevated indirect fraction indicates hemolysis or impaired uptake; elevated direct fraction indicates cholestasis or hepatocellular injury; in diabetics may reflect fatty liver disease
    • AST/ALT Elevation: >40 IU/L for AST or >56 IU/L for ALT suggests hepatocellular injury; AST >ALT pattern suggests chronic liver disease or hemolysis; ALT >AST suggests acute liver injury or fatty liver disease (NAFLD); both elevation indicates hepatitis; AST/ALT ratio used to assess fibrosis
    • Total Protein <6.0 g/dL indicates hypoproteinemia from malnutrition, liver disease, or renal losses; >8.3 g/dL suggests dehydration or myeloma; A/G ratio <1.0 indicates globulin excess (infection, autoimmune disease); >2.5 indicates albumin excess or globulin deficiency
    • GGT Elevation: >65 IU/L indicates cholestasis, hepatocellular disease, or alcohol-related liver damage; more specific for liver origin than ALP; correlates with oxidative stress and metabolic dysfunction
    • BUN Elevation: >20 mg/dL suggests kidney dysfunction, dehydration, or high protein diet; in diabetics indicates declining glomerular filtration; low BUN (<7 mg/dL) suggests malnutrition or liver disease; BUN rises disproportionately in prerenal azotemia (dehydration)
    • Creatinine Elevation: >1.3 mg/dL indicates reduced kidney function; in diabetics, even 'normal' creatinine may underestimate kidney disease in elderly or frail patients; creatinine doubles approximately when GFR is halved; rate of rise important for monitoring progression
    • eGFR <60 mL/min/1.73m² defines chronic kidney disease Stage 3 or higher; <30 indicates advanced kidney disease requiring specialist management; eGFR >60 with albuminuria still indicates kidney disease; used to adjust drug dosing and monitor progression
    • BUN/Creatinine Ratio >20 suggests dehydration, prerenal disease, or GI bleeding; <10 suggests overhydration, liver disease, or malnutrition; ratio helpful in distinguishing prerenal from intrinsic kidney disease
    • Urea (equivalent to BUN ÷ 2.8): Elevated urea reflects impaired kidney clearance; used in many countries outside USA; prognostic marker for kidney disease progression
    • Calcium <8.5 mg/dL suggests hypocalcemia from vitamin D deficiency, kidney disease, hypoparathyroidism; >10.2 mg/dL indicates hypercalcemia from hyperparathyroidism, malignancy, excess vitamin D; ionized calcium more accurate than total; corrected calcium calculated in hypoalbuminemia
    • Uric Acid Elevation: >7.2 mg/dL in males or >6.0 mg/dL in females raises gout risk, metabolic syndrome, kidney disease; in diabetics correlates with insulin resistance and cardiovascular risk; low uric acid (<2.0 mg/dL) suggests xanthine oxidase deficiency or uricosuric drugs
    • Total Cholesterol ≥240 mg/dL significantly increases cardiovascular risk in diabetics; 200-239 mg/dL borderline and warrants lifestyle modification; diabetics should aim for <200 mg/dL ideally; level influenced by age, diet, genetics, medications
    • LDL >160 mg/dL indicates high cardiovascular risk; diabetics should target LDL <70 mg/dL (very high risk) or <100 mg/dL (standard); LDL particle size and density matter (small dense particles more atherogenic); LDL calculated as (TC - HDL - Triglycerides/5)
    • HDL <40 mg/dL in males or <50 mg/dL in females is independent cardiovascular risk factor; each 1 mg/dL increase reduces risk ~2%; higher HDL protective even with elevated LDL; low HDL associated with insulin resistance and metabolic syndrome
    • Triglycerides ≥200 mg/dL (2.0 mmol/L) are independent cardiovascular risk factor and associated with small dense LDL; very high triglycerides (≥500 mg/dL) risk acute pancreatitis; triglycerides raised by high carbohydrate diet, obesity, alcohol, poorly controlled diabetes
    • VLDL Elevation >40 mg/dL suggests hypertriglyceridemia and metabolic dysfunction; VLDL particles pro-atherogenic; correlates with insulin resistance
    • Total/HDL Ratio <5.0 is desirable; >5.0 indicates increased cardiovascular risk; lower ratios with same total cholesterol preferable; important prognostic marker
    • LDL/HDL Ratio: Optimal <2.0; 2.0-3.0 desirable; >3.0 indicates increased cardiovascular risk; provides better prognostic value than LDL alone
    • Non-HDL >130 mg/dL indicates excess apoB-containing particles (LDL + VLDL); particularly useful when triglycerides elevated as more accurate than LDL; target <130 mg/dL for diabetics
    • TSH >4.0 mIU/L suggests primary hypothyroidism; <0.4 mIU/L suggests hyperthyroidism or overtreatment; abnormal TSH with normal free T4 suggests subclinical thyroid disease; hypothyroidism impairs glucose control and increases hypoglycemia risk
    • Total T3/T4 Abnormalities: Low T3 syndrome in severe illness; elevated free T3 with low TSH suggests Graves disease; pattern helps differentiate primary thyroid disease from pituitary/hypothalamic disease
    • HbA1c ≥6.5% confirms diabetes diagnosis; <5.7% is normal; 5.7-6.4% indicates prediabetes requiring lifestyle intervention; lower HbA1c targets (<7%) recommended for many diabetics to reduce complications; targets individualized by age, duration, and comorbidities; elevated HbA1c despite normal fasting glucose indicates postprandial hyperglycemia
    • eAG Interpretation: Calculated as (28.7 × HbA1c) - 46.7 in mg/dL; provides glucose equivalent of HbA1c; eAG 130 mg/dL corresponds approximately to HbA1c 6.5%; useful for patient education; less accurate at extremes of hemoglobin or in hemoglobinopathies
    • Amylase Elevation >110 IU/L suggests pancreatitis, though not specific (also elevated in parotitis, intestinal disease); amylase peaks and normalizes within 3-5 days in acute pancreatitis; chronic pancreatitis may have normal amylase; useful for acute presentation
    • Lipase Elevation >60 IU/L more specific than amylase for pancreatic injury; elevated longer than amylase (persists 8-14 days); lipase >3× upper limit suggests acute pancreatitis; must be interpreted with clinical presentation and imaging
    • Hemoglobin <12 g/dL in females or <13.5 g/dL in males indicates anemia; severity determines clinical significance; mild anemia often asymptomatic but affects oxygen delivery; causes include iron deficiency, B12/folate deficiency, chronic disease, hemolysis
    • Hematocrit <36% in females or <41% in males indicates anemia; percent change important for monitoring; rapid decline suggests acute bleeding or hemolysis; gradual decline suggests chronic anemia from nutritional deficiency or chronic disease
    • RBC Count <4.1 million/mcL in females or <4.5 million/mcL in males indicates anemia; indices (MCV, MCH, MCHC) determine type (microcytic, normocytic, macrocytic); helpful for etiology of anemia
    • WBC >11,000 suggests infection, inflammation, leukemia, or stress; <4,500 indicates leukopenia from bone marrow disease, medications, autoimmune disease; differential count identifies specific leukocyte abnormalities
    • Platelets <150,000 indicates thrombocytopenia increasing bleeding risk; >400,000 suggests thrombocytosis from inflammation, myeloproliferation, or iron deficiency; affects wound healing and infection risk
    • Sodium <136 mEq/L indicates hyponatremia from SIADH, medication, or dilution; >145 mEq/L indicates hypernatremia from dehydration or inadequate water intake; affects neurologic function, osmolality, and fluid balance
    • Potassium <3.5 mEq/L indicates hypokalemia from diuretics, diarrhea, or medications; >5.0 mEq/L indicates hyperkalemia risking arrhythmias and muscle weakness; critical in diabetics on ACE inhibitors/ARBs; affects cardiac conduction
    • Chloride <98 mEq/L suggests hypochloremia from vomiting, loop diuretics, or metabolic alkalosis; >107 mEq/L indicates hyperchloremia from diarrhea or metabolic acidosis; maintains electroneutrality
  • Associated Organs
    • Microalbumin: Kidneys - Assesses glomerular filtration integrity; early marker of diabetic nephropathy before decline in GFR; complications include progressive renal failure, end-stage renal disease, hypertension, cardiovascular disease
    • C-Peptide: Pancreas (beta cells) - Reflects endogenous insulin production from beta cell secretion; affected by diabetes type and duration; indicates residual beta cell function and prognosis
    • Iron Studies: Liver (primary storage), bones (marrow), GI tract - Iron metabolism affects multiple organs; hemochromatosis causes liver cirrhosis, cardiomyopathy, diabetes, arthropathy; iron deficiency affects oxygen delivery and immune function
    • Liver Function Tests: Liver - Assesses hepatocellular function, synthetic capacity, and cholestasis; complications of abnormal LFTs include fatty liver disease (NAFLD), cirrhosis, acute hepatitis, liver failure, variceal bleeding
    • Kidney Profile: Kidneys (primary) - Assesses glomerular filtration rate, tubular function, and electrolyte regulation; complications of chronic kidney disease include hypertension, anemia, bone disease, cardiovascular disease, progression to ESRD requiring dialysis
    • Lipid Profile: Liver (synthesis), intestines (absorption), blood vessels (deposition) - Assesses cardiovascular risk; abnormalities contribute to atherosclerosis, myocardial infarction, stroke, peripheral arterial disease, sudden cardiac death
    • Thyroid Profile: Thyroid gland (primary), pituitary (TSH regulation) - Assesses thyroid function and autoimmunity; thyroid disorders affect glucose metabolism, metabolic rate, lipid profile; autoimmune thyroiditis common in Type 1 diabetes
    • HbA1c/eAG: Red blood cells (measured in RBC) - Reflects glucose control at tissue level; complications of persistent hyperglycemia include microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (MI, stroke, PVD) disease
    • Insulin: Pancreas (beta cells), liver (metabolism), adipose tissue (receptor action) - Central to glucose homeostasis; abnormalities lead to diabetes, metabolic syndrome, PCOS, obesity complications
    • Pancreatic Profile: Pancreas (acinar cells) - Assesses pancreatic inflammation and function; complications include acute pancreatitis (severe pain, hypovolemia), chronic pancreatitis (malabsorption, diabetes), pancreatic insufficiency
    • CBC: Bone marrow (production), blood (circulation), spleen (destruction) - Assesses hematopoiesis and immune function; abnormalities affect oxygen delivery, infection risk, bleeding tendency, wound healing, immune response
    • Serum Electrolytes: Kidneys (regulation/excretion), GI tract (absorption), adrenal glands (aldosterone) - Critical for fluid balance, cardiac conduction, neuromuscular function; abnormalities cause arrhythmias, muscle weakness, seizures, altered mental status
  • Follow-up Tests
    • Microalbumin: If abnormal, repeat urine collection to confirm; 24-hour urine protein quantification if persistently elevated; renal ultrasound to assess kidney echogenicity; referral to nephrology if eGFR <30 or rapid decline; screening for kidney disease should be annual in all diabetics
    • C-Peptide: If low despite hyperglycemia, confirms Type 1 diabetes or advanced Type 2; if high with elevated glucose, indicates insulin resistance requiring lifestyle intervention and possible pharmacotherapy; can be repeated to track beta cell loss
    • Iron Studies: If transferrin saturation >50%, perform liver biopsy or MRI to assess for cirrhosis; screen first-degree relatives; repeat testing annually; if iron deficiency confirmed, investigate for GI bleeding; iron supplementation if deficient; consider phlebotomy if hemochromatosis diagnosed
    • Liver Function Tests: If ALT/AST elevated, repeat to confirm; ultrasound or FibroScan to assess fatty liver and fibrosis; if GGT/ALP disproportionately elevated, obtain right upper quadrant ultrasound for biliary obstruction; check viral hepatitis serology if indicated; referral to hepatology if concerning for cirrhosis
    • Kidney Profile: If abnormal, repeat in 2-4 weeks to confirm; measure 24-hour urine protein; renal ultrasound if eGFR <30; refer to nephrology if rapid decline or eGFR <30; assess for contrast-induced nephropathy if procedures planned; monitor annually in all diabetics; adjust medication doses for renal function
    • Lipid Profile: If abnormal, repeat fasting lipid panel in 4-12 weeks if lifestyle modifications initiated; assess 10-year cardiovascular risk using Framingham or ASCVD calculator; consider advanced lipid testing (particle size, Lp(a), apoB); start statin therapy if LDL elevated or diabetes present; monitor every 1-3 years if stable on therapy
    • Thyroid Profile: If TSH abnormal, measure free T4 to characterize dysfunction; if free T4 abnormal, check thyroid antibodies (TPO, thyroglobulin) for autoimmune thyroiditis; repeat TSH annually if subclinical hypothyroidism; screen for thyroid disease every 1-5 years in Type 1 diabetes; initiate levothyroxine if TSH >10 or <0.1
    • HbA1c: Retest every 3 months if <7% target not achieved; every 6 months if at goal and stable; annual in stable patients; eAG correlates glucose control with complications; home glucose monitoring if HbA1c >8%; continuous glucose monitoring if HbA1c >8% or frequent hypoglycemia
    • Insulin: Calculate HOMA-IR if concerned about insulin resistance (fasting insulin × fasting glucose / 405); if elevated, intensify lifestyle modifications; consider GLP-1 agonists or SGLT2 inhibitors; reassess after lifestyle changes or medication initiation
    • Pancreatic Profile: If amylase or lipase elevated, repeat measurement to establish trend; abdominal ultrasound or CT if pancreatitis suspected; lipase >3× upper limit warrants imaging; evaluate for choledocholithiasis, hypertriglyceridemia, alcohol use; hospitalize if acute pancreatitis confirmed
    • CBC: If hemoglobin low, measure iron studies and B12/folate; reticulocyte count to assess bone marrow response; peripheral smear for cell morphology; if WBC elevated, repeat to confirm; if WBC <4,500, repeat and consider hematology referral; monitor platelet trend
    • Electrolytes: If abnormal, check for dehydration, medication effects, or underlying disease; obtain ECG if potassium <3.0 or >6.0; hyponatremia workup includes serum osmolality and urine osmolality; repeat measurement acutely if severe abnormalities; urgent intervention if symptoms present
  • Fasting Required?
    • YES - Fasting for 8-12 hours is required for the Advanced Diabetic Package
    • Fasting Duration: 8-12 hours recommended; ideally 10 hours overnight fasting; 8-10 hours minimum acceptable; longer than 12 hours not necessary and may affect some results
    • Fasting Components: No food or calorie-containing beverages; water allowed; black coffee or tea without milk/sugar acceptable; no juice, sports drinks, or energy drinks; avoid chewing gum (contains sugar/non-nutritive sweeteners affecting results)
    • Medications: Continue all regular medications unless specifically instructed otherwise; inform phlebotomist of all medications; some medications affect test results (metformin for renal function, lipid-lowering drugs, corticosteroids); discuss with physician if medication effects concern you
    • Insulin Administration: Continue insulin injections/infusions as scheduled; do NOT skip doses; inform lab technician if insulin given to allow for proper test interpretation
    • Exercise: Avoid strenuous exercise 24 hours before testing; excessive activity can raise liver enzymes and affect glucose results; light activity acceptable
    • Alcohol: Avoid alcohol for 24 hours before testing; alcohol affects liver enzymes, lipids, glucose, and electrolytes; interferes with test interpretation
    • Stress: Minimize stress before blood draw; stress hormones affect glucose, cortisol, and CBC results; arrive early to reduce testing anxiety
    • Timing: Schedule blood draw in morning (7-9 AM) if possible; fasting state most pronounced in early morning; afternoon testing acceptable if 8+ hour fasting maintained
    • Urine Microalbumin: May require 24-hour urine collection (confirm with lab); if collecting, start collection in morning after first void (discard), collect all urine for 24 hours, end collection with first morning void next day; refrigerate collection; transport promptly
    • Special Circumstances: If diabetic and taking insulin/medications for hypoglycemia, consult physician about testing day management; have carbohydrate source available after testing; women should avoid testing during menstrual cycle if possible (can affect CBC); report fever, infections, or recent illness to phlebotomist

How our test process works!

customers
customers